208 related articles for article (PubMed ID: 18566690)
1. Structural Development Studies of Subtype-Selective Ligands for Peroxisome Proliferator-Activated Receptors (PPARs) Based on the 3,4-Disubstituted Phenylpropanoic Acid Scaffold as a Versatile Template.
Miyachi H; Hashimoto Y
PPAR Res; 2008; 2008():689859. PubMed ID: 18566690
[TBL] [Abstract][Full Text] [Related]
2. [PPARgamma targeted genome-based drug discovery; present and future direction].
Miyachi H
Nihon Rinsho; 2010 Feb; 68(2):243-8. PubMed ID: 20158091
[TBL] [Abstract][Full Text] [Related]
3. Structural Biology-Based Exploration of Subtype-Selective Agonists for Peroxisome Proliferator-Activated Receptors.
Miyachi H
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502131
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism.
Latruffe N; Vamecq J
Biochimie; 1997; 79(2-3):81-94. PubMed ID: 9209701
[TBL] [Abstract][Full Text] [Related]
5. Biology and therapeutic applications of peroxisome proliferator- activated receptors.
Menendez-Gutierrez MP; Roszer T; Ricote M
Curr Top Med Chem; 2012; 12(6):548-84. PubMed ID: 22242855
[TBL] [Abstract][Full Text] [Related]
6. [Design and synthesis of subtype- and species-selective peroxisome proliferator-activated receptor (PPAR) alpha ligands].
Miyachi H
Yakugaku Zasshi; 2004 Nov; 124(11):803-13. PubMed ID: 15516807
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and structure-activity relationship study of peroxisome proliferator-activated receptor (PPAR) delta-selective ligands.
Miyachi H
Curr Med Chem; 2007; 14(22):2335-43. PubMed ID: 17896982
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype.
Kuwabara N; Oyama T; Tomioka D; Ohashi M; Yanagisawa J; Shimizu T; Miyachi H
J Med Chem; 2012 Jan; 55(2):893-902. PubMed ID: 22185225
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the 'future' in dermatology therapeutics?
Gupta M; Mahajan VK; Mehta KS; Chauhan PS; Rawat R
Arch Dermatol Res; 2015 Nov; 307(9):767-80. PubMed ID: 25986745
[TBL] [Abstract][Full Text] [Related]
10. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation.
Schoonjans K; Staels B; Auwerx J
Biochim Biophys Acta; 1996 Jul; 1302(2):93-109. PubMed ID: 8695669
[TBL] [Abstract][Full Text] [Related]
11. [Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control].
Bocher V; Chinetti G; Fruchart JC; Staels B
J Soc Biol; 2002; 196(1):47-52. PubMed ID: 12134632
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptors, orphans with ligands and functions.
Schoonjans K; Martin G; Staels B; Auwerx J
Curr Opin Lipidol; 1997 Jun; 8(3):159-66. PubMed ID: 9211064
[TBL] [Abstract][Full Text] [Related]
13. Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands.
Merk D; Lamers C; Weber J; Flesch D; Gabler M; Proschak E; Schubert-Zsilavecz M
Bioorg Med Chem; 2015 Feb; 23(3):499-514. PubMed ID: 25583100
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall.
Chinetti G; Fruchart JC; Staels B
Z Kardiol; 2001; 90 Suppl 3():125-32. PubMed ID: 11374025
[TBL] [Abstract][Full Text] [Related]
15. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
Gervois P; Fruchart JC; Staels B
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases.
Sertznig P; Seifert M; Tilgen W; Reichrath J
Am J Clin Dermatol; 2008; 9(1):15-31. PubMed ID: 18092840
[TBL] [Abstract][Full Text] [Related]
17. Recent progress in research on peroxisome proliferator-activated receptor alpha-selective ligands.
Miyachi H
IDrugs; 2004 Aug; 7(8):746-54. PubMed ID: 15334308
[TBL] [Abstract][Full Text] [Related]
18. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
Yumuk VD
Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
[TBL] [Abstract][Full Text] [Related]
19. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
Huang TH; Roufogalis BD
Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome.
Kasuga J; Yamasaki D; Araya Y; Nakagawa A; Makishima M; Doi T; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2006 Dec; 14(24):8405-14. PubMed ID: 16996742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
